Rare disease drug market seen growing to $425 billion by 2034
AI Summary- Hanmi Pharmaceutical presented phase 2 results for congenital hyperinsulinemia candidate efpegerglucagon.
- $222.8 billion market is expected to reach $425 billion by 2034.
- Hanmi and Yuhan candidates received orphan-drug designations in the U.S. and Europe.